Royalty Pharma (RPRX) EBITDA (2019 - 2026)

Royalty Pharma has disclosed EBITDA across 8 years of filings, most recently posting $563.0 million for Q1 2026.

• EBITDA for Q1 2026 came in at $563.0 million, up 5.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 billion (down 16.42% YoY), and the FY2025 annual result was $1.6 billion, up 20.66% from the prior year.
• EBITDA came in at $563.0 million for Q1 2026 at Royalty Pharma, up from $388.4 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $735.1 million in Q3 2024 to a low of -$482.7 million in Q4 2022.
• The 5-year median for EBITDA is $361.5 million (2024), against an average of $306.7 million.
• Across the five-year window, EBITDA plunged 414.6% in 2022 and soared 824.08% in 2025, its largest moves.
• Royalty Pharma's EBITDA stood at -$482.7 million in 2022, then soared by 226.98% to $612.9 million in 2023, then sank by 41.02% to $361.5 million in 2024, then grew by 7.43% to $388.4 million in 2025, then soared by 44.97% to $563.0 million in 2026.
• The last three EBITDA figures came in at $563.0 million (Q1 2026), $388.4 million (Q4 2025), and $427.2 million (Q3 2025), per Business Quant data.